AA
GALT icon

Ancora Advisors’s Galectin Therapeutics GALT Stock Holding History

Ancora Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-52,380
Closed -$222K – 2465
2025
Q3 		$222K Buy
52,380
+39,380
+303% +$148K ﹤0.01% 703
2025
Q2 		$27.4K Hold
13,000
– – ﹤0.01% 1152
2025
Q1 		$15.9K Buy
+13,000
New +$18.2K ﹤0.01% 1236

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ancora Advisors's GALT Position: Q4 2025 in Review

Ancora Advisors sold out of Galectin Therapeutics (GALT) in Q4 2025, closing a stake of 52,380 shares — an estimated $222K sold.

Ancora Advisors first reported a position in GALT in Q1 2025 and held it in 3 quarters. The position peaked at $222K in Q3 2025. 97 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

  • Ancora Advisors reported no remaining Galectin Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ancora Advisors sold 52,380 Galectin Therapeutics shares in Q4 2025, an estimated $222K.
  • Ancora Advisors first reported a position in Galectin Therapeutics in Q1 2025 and held it in 3 quarters.
  • Ancora Advisors's Galectin Therapeutics position peaked at $222K in Q3 2025.
  • 97 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on Ancora Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.